Email this article Effective control of a severe exacerbation of bronchial asthma
- Authors: Makolkin VI1, Ovcharenko SI1, Peredelskaya OA1
-
Affiliations:
- Issue: Vol 79, No 8 (2004)
- Pages: 48-50
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29896
- ID: 29896
Cite item
Full Text
Abstract
Aim. To evaluate effectiveness and safety of nebulizer therapy (NT) with broncholytics and pulmicort
suspension (PS) in patients with a severe exacerbation of bronchial asthma (BA).
Material and methods. 75patients with a severe BA exacerbation received broncholytic NT with consideration of comorbid pathology and age. Nebulized PS was used as an alternative to systemic glucocorticosteroids (SGCS). NT efficacy was assessed by changes in clinical symptoms, in the peak expiration velocity (PEV) and spirometry parameters. Safety was controlled by 24-h ECG monitoring, pulsoximetry. PS was examined for effect on adrenal cortex, calcium metabolism, oral infection with
Candida. Side effects were registered.
Results. Clinical improvement was recorded in all the patients. NT reduced the number of additional
inhalations of short-acting beta2-agonists 4-5 times, on the average. In the end of NT there was a
4.66% increase in Sa02 vs the initial value (p - 0.04). PEV and FEVl increased. Plasm levels of hydrocortisone and its urine excretion did not lower vs initial values.
Conclusion. The results of the study point to efficacy and safety of combined NT with broncholytics
and PS in a severe exacerbation of В A.
suspension (PS) in patients with a severe exacerbation of bronchial asthma (BA).
Material and methods. 75patients with a severe BA exacerbation received broncholytic NT with consideration of comorbid pathology and age. Nebulized PS was used as an alternative to systemic glucocorticosteroids (SGCS). NT efficacy was assessed by changes in clinical symptoms, in the peak expiration velocity (PEV) and spirometry parameters. Safety was controlled by 24-h ECG monitoring, pulsoximetry. PS was examined for effect on adrenal cortex, calcium metabolism, oral infection with
Candida. Side effects were registered.
Results. Clinical improvement was recorded in all the patients. NT reduced the number of additional
inhalations of short-acting beta2-agonists 4-5 times, on the average. In the end of NT there was a
4.66% increase in Sa02 vs the initial value (p - 0.04). PEV and FEVl increased. Plasm levels of hydrocortisone and its urine excretion did not lower vs initial values.
Conclusion. The results of the study point to efficacy and safety of combined NT with broncholytics
and PS in a severe exacerbation of В A.
References
- Kashevskaya
- Чучалин А. Г. (ред.) Бронхиальная астма, глобальная стратегия лечения и профилактики бронхиальной астмы. Пересмотр 2002 г. М.: Изд-во "Атмосфера", 2002.
- Руководство по диагностике и лечению бронхиальной астмы - Expert panel report-2: Пер. с англ. под ред. А. Н. Цой. М.; 1998.
- Чучалин А. Г., Медников Б. Л., Белевский А. С. и др. Бронхиальная астма: руководство для врачей России. Consilium Medicum 2000; 2(1): 11-21.
- The British Guidelines on Asthma Management: 1995 review and position statement. Thorax 1997; 52 (suppl.l): 1-21.
- Beasley R., Hendeles L. Preservatives in nebulizer solutions: risks without benefits, a further comment. Pharmacotherapy 1999; 19: 473-474.
- Bremner P., Burgess C, McHaffie D. et al. The effect of hypercapnia and hypoxenia on the cardiovascular responses to isoproterenol. Clin. Pharmacol. Ther. 1994; 56: 302-308.
- Ольбинская Л. И., Игнатенко С. Б. Синдром удлиненного интервала QT. Клин, фармакол. и тер. 1999; 8 (5): 44-46.
- Черняк Б. А., Краснова Ю. Н., Дзизинский А. А. Эффективность и безопасность бронхолитической небулайзерной терапии при лечении обострений бронхиальной астмы у больных с ишемической болезнью сердца. Рос. мед. журн. 2001; 12: 24-26.
- Алексеев В. Г., Яковлев В. Н., Синопальников А. И. Бронхиальная астма. В кн: Очерки клинической пульмонологии. М; 1998. 87-128.
- Pedersen S. Study with nebulised budesonide. In: Budesonide nebulising suspension. Oxford clinical communications. Oxford; 1989. 25-27.
Supplementary files
